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Abstract
Objective: Occult clinical presentations usually hinder the early detection and management of patients with bone metastases 
from thyroid carcinoma. We retrospectively investigated the clinical outcomes of such patients from 1993 to 2004 and 
analyzed the prognostic parameters.
Design: The basic demographic data and manifestations of 44 patients who had thyroid carcinoma with bone metastases 
were reviewed. We studied the gender, age, locations of metastases, histological types, treatment methods, hypercalcemic 
episodes and results of treatments. We used Kaplan-Meier survival analysis and log-rank tests to access the statistical sig-
niﬁ  cance.
Main outcome: The incidence of bone metastasis from thyroid carcinomas in this series was 5.0%. Twenty patients (45.4%) 
had follicular, 16 (36.3%) had papillary, 3 (6.8%) had anaplastic, 3 (6.8%) had medullary, and 2 (4.5%) had Hurthel cell 
carcinomas. Twelve patients had hypercalcemic episodes, ranging from 2.6 to 2.9 mmolL
−1 (mean ± SD: 2.68 ± 0.15 mmolL
−1). 
Survival time after bone metastases ranged from 2 months to 8 years (mean ± SD: 5.3 ± 1.3 years). The 5-year survival rate 
was 79.4% and the 10-year survival rate was 52.9%. Regarding the histological cancer type, patients with papillary and 
follicular cancers survived signiﬁ  cantly longer than those with anaplastic and medullary cancers (p  0.05). In addition, 
the patients presenting with hypercalcemia had the worst survival (p  0.05).
Conclusions: Thyroid carcinoma can present with bone metastases in its early stage. We found that both tumor type and 
hypercalcemia were signiﬁ  cant prognostic factors for survival time.
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Introduction
Carcinoma of the thyroid gland is one of the possibly curable cancers.
15 At the time of initial diag-
nosis, 1%–3% of patients with thyroid cancer may have distant metastases, whereas another 7%–23% 
will develop distant metastases during the disease course.
3,14,16 Yet, occult clinical presentations 
usually delay the early diagnosis and management of these metastases. The distant metastases, espe-
cially those involving bone, increase mortality rate, compromise quality of life and shorten patient 
survival.
9,14
The imaging techniques to detect bone metastatic lesions include plain radiography, computed 
tomography (CT), magnetic resonance imaging (MRI), isotope bone scans, positron emission tomog-
raphy (PET),
4 radioiodine uptake, and others. The management of primary thyroid cancer is multidis-
ciplinary, including surgeons, endocrinologists, nuclear medicine physicians, and radiotherapists.
19 The 
5-year survival rates for patients with bone metastases ranged from 53% to 84% in previous 
reports.
1,2,16
Although the estimated incidence of thyroid cancer has increased by 14.6% over the past 40 years, 
the estimated death rate has fallen by 21%, probably as a result of earlier diagnosis.
18 Furthermore, 
trends toward smaller tumor size, less advanced clinical stage, longer disease-free survival, and lower 
mortality rates after 1993 was also noted in Taiwan.
6 This ﬁ  nding emphasizes the importance of its 
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early detection and proper treatment. In this study, 
we investigated 44 patients with thyroid cancers 
and bone metastases that were treated in our hos-
pital from January 1993 to June 2004. The aim of 
this study was to investigate the prognostic factors 
of the patients with bone metastases due to thyroid 
cancer.
Materials and Methods
From January 1993 to June 2004, there were 887 
patients with thyroid carcinomas were treated at 
author’s hospital. Forty-four patients (5.0%) of the 
887 patients had bone metastases. The medical 
records of the 44 patients were reviewed. We 
investigated the follow-up period, gender, age, 
clinical manifestations, locations of metastases, 
treatment methods, hypercalcemia episodes and 
results of the treatment.
Thyroid carcinomas in this series were histo-
pathologically classiﬁ  ed as follicular, papillary, 
Hurthel, medullary and anaplastic carcinoma. Bone 
metastatic lesions were detected by using plain 
skeletal radiograms, computed tomography (CT), 
magnetic resonance imaging (MRI), isotope bone 
scan, or radioiodine uptake either on routine follow 
up or as directed by the patients’ symptoms. There 
were wide variations of clinical presentations, 31 
(70.4%) patients presenting skeletal pain or neu-
rological symptoms caused by vertebral metastatic 
lesions, 4 (9.09%) presenting pathological fractures 
in the extremities, 6 (13.6%) asymptomatic and 
were found to have bone metastases incidentally 
on the radioisotope scan. Thyroid origin of meta-
static disease was conﬁ  rmed by pathological report 
from surgical specimen or presence of radioiodine 
uptake. For the patients who had received thyroid-
ectomized, we have reviewed their pathology 
report.
The patients were treated according to the fol-
lowing guidelines. Radioactive iodine 
131I was 
given when bone lesions were detected using 5mCi 
131I diagnostic scans. These patients were treated 
with 
131I radiotherapy to the maximum permissible 
dose based on quantitative dosimeter studies.
5,17 
Twelve patients in our study were treated with 
131I 
for metstatic lesion, with a mean cumulative dose 
of 319 ± 105 mCi (range: 31–502 mCi). 
131I thera-
pies were repeated if the follow-up 
131I scan 
showed residual or persistent metastatic bone 
lesions. External radiotherapy was also applied to 
treat lesions that were painful and could not be 
removed by surgery. Local bone surgery was 
indicated only for decompression, open reduction 
and internal ﬁ  xation of pathologic fractures, and 
tumor resection or for diagnostic biopsy. All these 
patients underwent post-operation 
131I treatment. 
In general, these patients were followed up regu-
larly, with 5 mCi 
131I diagnostic scans, plain chest 
radiogram, and plain radiograms of metastatic bone 
areas performed every 6 months or one year.
We used Kaplan-Meier method to analyze the 
survival curves, and used the log-rank test to assess 
the statistical differences among the different 
groups with respect to survival functions. Survival 
time was deﬁ  ned as time of follow up after diag-
nosis of bone metastasis. A p value less than 0.05 
was considered to be statistically signiﬁ  cant.
Results
The demographic data of the patients are shown in 
Table 1. The age at the time of diagnosis ranged 
from 12 to 85 years (mean 62.1 years). Thirty-three 
patients (75%) were females and 11 (25%) were 
males. The primary histological classification 
included 20 (45.4%) follicular, 16 (36.3%) papil-
lary, 3 (6.8%) anaplastic, 3 (6.8%) medullary, and 
2 (4.5%) Hurthel cell carcinomas (Table 1).
Among the total 887 patients treated, 137 
(15.4%) patients had follicular carcinoma, 598 
(67%) papillary, 44 (5%) anaplastic, 25 (2.8%) 
medullary and 25 (2.8%) Hurthel cell carcinoma. 
The original bone metastatic rate was estimated to 
be 14.5% (20/137) for follicular carcinoma, 2.7% 
(16/598) for papillary carcinoma, 6.8% (3/44) for 
anaplastic carcinoma, 12% (3/25) for medullary 
carcinoma and 8% (2/25) for Hurthel cell 
carcinoma.
Twelve patients were noted to have hypercal-
cemia episodes, ranging from 2.6 to 2.9 mmolL
-1 
(mean 2.68 mmolL
-1). Their mean survival time 
was 9.57 months (range 2–16.2 moths).
As the presenting symptoms, 25 (56.8%) 
patients had pain as the initial presenting symptom, 
8 (18.1%) with a protruding mass, 6 (13.6%) had 
cord compression, 4 (9.1%) with pathological 
fracture, and 7 (16.0%) had bone metastases inci-
dentally found on radioisotope scan. All of the 
metastases showed osteolytic lesions on radio-
grams.
Twenty-three patients (52.2%) presented with 
bone metastases before the thyroid cancers were 
diagnosed. Among them, 17 (74.0%) patients had 
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pain as the initial presenting symptom, 3 (13%) 
patients with pathological fracture, and 3 (13%) 
patients with metastases incidentally found on 
radioisotope scan. Twenty ﬁ  ve patients (56.8%) 
had multiple sites of bone metastases noted from 
the initial work up studies. Vertebrae 23(52.2%), 
femur 9(20.4%), skull 7(16.0%), pelvis 7(15.9%), 
and clavicle 6(13.6%) were the most common sites 
of metastases.
Of the 44 patients, surgical treatment was per-
formed in 17 patients: nine patients (5 lumbar-spine 
lesions, 4 thoracic-spine lesions) with vertebral 
metastasis underwent decompression laminec-
tomy; 8 patients with pathological fracture 
(5 femur, 4 tibia, 3 at humerus) received open 
reduction and internal ﬁ  xation. Four complications 
occurred, including 3 postoperative infections and 
postoperative hemorrhage. All 17 patients had 
symptoms relieved after operation.
Using Kaplan-Meier method, the 5-year sur-
vival rate was 79.4%, the 10-year survival rate 
was 52.9% (Fig. 1). The 5-year survival rate was 
64.2% for papillary cancer, 82% for follicular 
cancer, 0% for anaplastic cancer, 100% for Hurthel 
cell cancer and 61% for medullary cancer. With 
log rank analysis, we found that the patients with 
papillary cancer and follicular cancer signiﬁ  cantly 
survive longer than those with the anaplastic 
type and medullary cancer (p  0.05) (Fig. 2A). 
The patients presenting hypercalcemia had a worse 
survival (5-year survival rate 84% v.s. 55%) 
(p  0.05) (Fig. 2D). The 5-year survival rate for 
single bone metastasis was 81.2% and 80.4% for 
multiple bone metastases, which didn’t show 
signiﬁ  cant difference (Fig. 2B). The 5-year sur-
vival rate 70.6% when did not undergo any surgi-
cal treatment as compared with 80.2% for whom 
treated with surgical methods, which didn’t show 
signiﬁ  cant difference, either (Fig. 2C). The 5-year 
survival rate also didn’t show any differnce 
between different genders. (female v.s. male, 
83.1% v.s. 64.6%)(Fig. 2E).
On the other hand, gender, age, clinical mani-
festations, locations of metastases, and treatment 
methods did not show signiﬁ  cant difference by log 
rank analysis (Fig. 2 A~E). Although the patients 
with multiple bone metastasis seemed to have a 
worse survival, the difference is not signiﬁ  cant.
The mean survival time was 9.6 months (range, 
2.0–16.2 months). The survival time after bone 
Table 1. Demographic data of the patients with bone metastases form thyroid carcinoma.
Follicular Papillary Anaplastic Hurthel  cell Medullary  Total 
(N = 20) (N = 16) (N = 3) (N = 2) (N = 3) (N = 44)
Age 62.3 64.2 69.6 66.5 39.0 62.1
Female: Male 18:2 12:4 2:1 1:1 0:3 33:11
Pain 7 11 3 1 3 25 (56.8%)
Protruding 
mass
4 3 0 1 0 8 (18.1%)
Nerologic 
symptoms
1 2 0 0 0 6 (13.6%)
Fractures 3 1 0 0 0 4 (9.1%)
Hypercalcemia 4 6 1 0 1 12 (27.3%)
Multiple 
metastasis 13 7 2 2 1 25 (56.8%)
Figure 1. Survivor-ship curve as determined by Kaplan- Meier 
method, the 5-year survival rate was 79.4%, the 10-year survival rate 
was 52.9%.
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metastases ranged for 2 months to 8 years (mean 
± SD: 5.3 ± 1.3 years).
Discussion
Bone metastases from aggressive thyroid carci-
noma may cause serious complications. Unfortu-
nately, the occult clinical presentations usually 
delay the early diagnosis and proper management. 
We conducted a retrospective analysis of prognos-
tic factor in 44 patients with thyroid cancers and 
bone metastases during the period of January 1993 
to June 2004. The results showed the signiﬁ  cant 
prognostic values of hypercalcemia and bone 
tumor types.
Figure 2. Kaplan – Meier plot of surviving after diagnosis of bone metastasis. The results showed that both tumor type and hypercalcemia 
were the signiﬁ  cant prognostic factors (p  0.05). (A) The 5-year survival rate was 64.2% for papillary cancer, 82.0% for follicular cancer, 
0% for anaplastic cancer, 100% for Hurthel cell cancer and 61.1% for medullary cancer. (B) The 5-year survival rate for single bone metas-
tasis was 81.2% and 80.4% for multiple bone metastases. (C) The 5-year survival rate 80.2% when treated with surgical method and 70.6% 
when treated without surgical method. (D) The 5-year survival rate for patients who have no hypercalcemia episode noted during the course 
of treatment was 84.0% and only 55.0% when more than one episode of hypercalcemia was noted. (p  0.05) (E) The 5-year survival rate 
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Of the 887 patients with thyroid carcinomas treated 
at author’s hospital, 44 patients (5.0%) had bone 
metastases. The overall prevalence rate was similar 
to previous reports (3.8%–4.2%).
7,11 Female patients 
(75%) were also more common than male (25%) as 
in previous reports (female, 82.7%; male 17.9%).
2
The higher occurrence rate of bone metastases 
in follicular histotype (14.5%) than with papillary 
histotype (2.7%) has been observed in other 
series.
7,11 The original bone metastatic rate in this 
series (14.5%) was similar in follicular carcinoma 
in the other series (15%–17%).
2,7 However, bone 
metastases rate (2.7%) in papillary carcinoma was 
higher than that of Marcocci (0.6%).
7 Differences 
in the referral pattern of patients may account for 
such discrepancy.
The distribution of osseous metastases in our 
series was similar to that observed by other authors 
with the spine and femur as the most common 
sites.
7,8 Vertebrae 23(52.2%), femur 9(20.4%), 
skull 7(16.0%), pelvis 7(16.0%) and clavicle 
6(13.6%) were the most common sites of metas-
tases. Besides, multiple bone lesions occurred more 
frequently (56.8%) than single bone lesion, which 
was same to the report from Pittas and Fanchiag 
(53%; 79.5% respectively).
2,10
As the initial presenting symptoms, 25(56.8%) 
patients had pain, 8(18.1%) patients with a protrud-
ing mass, six patients with cord compression, 
4(9.1%) patients with pathological fracture, and 
7(16.0%) patients had bone metastases incidentally 
found on radioisotope scan. This presenting symp-
toms and signs were similar to previous report.
2
Patients with bone metastases of unknown ori-
gin are not rarely encountered, and the primary 
tumor is frequently found in the lung, breast, and 
prostate.
13 It is worth noting that 23/44(52.2%) of 
our patients had the bone metastases as their initial 
presenting symptoms of thyroid cancer. The rela-
tive high incidence of bone metastasis in the 
patients with thyroid cancer makes it important to 
take it into consideration as a possible underlying 
lesion for those with skeletal metastatic diseases 
of unknown primary origin.
Surgical treatment was performed for 17/44 
patients: nine patients with vertebral metastasis 
underwent decompression laminectomy; eight 
patients with pathological fractures underwent 
open reduction and internal ﬁ  xation combined with 
palliative surgery. Although that surgical treatment 
was not a signiﬁ  cant prognostic indicator in our 
study, it appears from these data that surgical 
treatment of metastases from thyroid cancer 
achieved good functional outcomes even in cases 
where neurological or mechanical complications 
had occurred. Other reports of surgical removal of 
respectable metastases also had favorable effects 
on the prognosis.
9 Therefore, proper surgery to 
prevent or treat complications of metastatic bone 
disease appears to be a useful adjunct to improve 
morbidity in patients with skeletal disease.
The survival rate for patients with lung or bone 
metastases from thyroid gland was 53% at 5 year, 
38% at 10 year, as described by Schlumberger 
et al.
16 Ruegemer el al.
14 found the 5 year survival 
rate to be 92% for age younger than 40 with a 
single organ metastatic lesion and a 5 year survival 
rate of 35% for those whose age were older than 
40 with a single organ metastatic lesion form dif-
ferentiated thyroid carcinoma. Using Kaplan-Meier 
method, the 5-year survival rate in our series was 
estimated to be 79.4%, and the 10-year survival 
rate was 52.9% (Fig. 1). A higher 5-year survival 
rate, and a higher 10-year survival rate in our series 
as compared with the report from Schlumberger 
et al.
16 was noted (79.4 vs. 53%, 52.9 vs. 38%, 
respectively). The differences in the survival rate 
may be due to the different patient population and 
the different tumor subtype.
With log rank analysis, we found that tumor type 
and hypercalcemia were the prognostic factors 
(p  0.05) (Fig. 2). Gender, age, clinical manifes-
tations, locations of metastases, multiple bone 
metastasis and treatment methods did not show 
signiﬁ  cant differences, which were compatible with 
the ﬁ  ndings of previous reports.
10 Poor life expec-
tancy in cancer associated hypercalcemia was 
previously described by Stuart et al.
12 However, 
thyroid cancer associated hypercalcemia has not 
been well described before. Our data indicated that 
hypercalcemia in patients with thyroid cancer and 
bone metastases signiﬁ  es a grave prognosis. We 
could not ﬁ  nd a correlation between hypercalcemia 
and thyroidectomized status. For the patients who 
had received thyroidectomized, we have reviewed 
their pathology report and none have shown to have 
coincidence parathyroid tissue within the specimen. 
It is still unclear about whether this association is 
due to death from hypercalcemic crises or to the 
fact that the development of hypercalcemia is sim-
ply a marker of tumor biological behavior, indicat-
ing more advanced disease.
There are several limitations to the present 
study. First, since these data collected where from 
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a tertiary referral medical center, the prevalence 
rate and the presentations of the patients could be 
different than that from the general population. 
Second, the numbers of patients with anaplastic, 
medullary, and Hurthel cell carcinoma were 
limited, which made statistical evaluation difﬁ  cult. 
Further study design with a larger number of sub-
jects is necessary to conﬁ  rm our results.
In conclusion, thyroid carcinoma can present 
with bone metastases in its early stage. Early detec-
tion and management should help disease control 
and improve patients’ quality of life. A high index 
of suspicion is needed to detect these early bone 
metastases at the initial visit, allowing prompt and 
thorough follow-up during clinical practice. Our 
data showed that hypercalcemia and original tumor 
cell type are the prognostic factors.
References
[1]  Chen, M.H., Chang, C.C., Huang, T.S. et al. 2003. Factors affecting 
long-term survival of Taiwanese patients with medullary thyroid 
carcinoma. J. Formos. Med. Assoc, 102:73.
[2]  Fanchiang, J.K., Lin, J.D., Huang, M.J. et al. 1998. Papillary and 
follicular thyroid carcinomas with bone metastases: a series of 39 
cases during a period of 18 years. Changgeng Yi Xue Za Zhi, 
21:377.
[3] Harness,  J.K., Thompson, N.W., Sisson, J.C. et al. 1974. Proceedings: 
Differentiated thyroid carcinomas. Treatment of distant metastases. 
Arch. Surg., 108:410.
[4]  Iwata, M., Kasagi, K., Misaki, T. et al. 2004. Comparison of whole-
body 18F-FDG PET, 99mTc-MIBI SPET, and post-therapeutic 
131I-Na scintigraphy in the detection of metastatic thyroid cancer. 
Eur. J. Nucl. Med. Mol. Imaging, 31:491.
[5]  Leeper, R.D. 1973. The effect of 131 I therapy on survival of patients 
with metastatic papillary or follicular thyroid carcinoma. J. Clin. 
Endocrinol. Metab., 36:1143.
[6]  Lin, J.D., Chao, T.C., Sun, J.H. et al. 2000. Trends in the clinical 
characteristics of patients with papillary thyroid carcinoma in Taiwan. 
Oncology, 58:280.
[7]  Marcocci, C., Pacini, F., Elisei, R. et al. 1989. Clinical and biologic 
behavior of bone metastases from differentiated thyroid carcinoma. 
Surgery, 106:960.
[8]  McCormack, K.R. 1966. Bone metastases from thyroid carcinoma. 
Cancer, 19:181.
[9]  Niederle, B., Roka, R., Schemper, M. et al. 1986. Surgical treatment 
of distant metastases in differentiated thyroid cancer: indication and 
results. Surgery, 100:1088.
[10]  Pittas, A.G., Adler, M., Fazzari, M. et al. 2000. Bone metastases from 
thyroid carcinoma: clinical characteristics and prognostic variables 
in one hundred forty-six patients. Thyroid, 10:261.
[11]  Proye, C.A., Dromer, D.H., Carnaille, B.M. et al. 1992. Is it still 
worthwhile to treat bone metastases from differentiated thyroid 
carcinoma with radioactive iodine? World J. Surg., 16:640.
[12]  Ralston, S.H., Gallacher, S.J., Patel, U. et al. 1990. Cancer-associated 
hypercalcemia: morbidity and mortality. Clinical experience in 126 
treated patients. Ann. Intern. Med., 112:499.
[13]  Rougraff, B.T. 2003. Evaluation of the patient with carcinoma of 
unknown origin metastatic to bone. Clin. Orthop., S105.
[14]  Ruegemer, J.J., Hay, I.D., Bergstralh, E.J. et al. 1988. Distant metas-
tases in differentiated thyroid carcinoma: a multivariate analysis of 
prognostic variables. J. Clin. Endocrinol. Metab., 67:501.
[15]  Schlumberger, M., Baudin, E. and Travagli, J.P. 1998. [Papillary and 
follicular cancers of the thyroid]. Presse Med., 27:1479.
[16]  Schlumberger, M., Tubiana, M., De Vathaire, F. et al. 1986. Long-term 
results of treatment of 283 patients with lung and bone metastases 
from differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab., 
63:960.
[17]  Van Nostrand, D., Neutze, J. and Atkins, F. 1986. Side effects of 
"rational dose" iodine-131 therapy for metastatic well-differentiated 
thyroid carcinoma. J. Nucl. Med., 27:1519.
[18]  Vini, L. and Harmer, C. 2002. Management of thyroid cancer. Lancet 
Oncol., 3:407.
[19]  Vini, L., Harmer, C. and McCready, V.R. 1996. Thyroid cancer: a 
review of treatment and follow-up. Ann. Nucl. Med., 10:1.
134